Given that HNRNPA1 and IGF2BP2 have been widely discovered to be able to regulate the progression of various cancers, including HCC (Simon et al., 2014; Wen et al., 2020), these two candidate RBPs were selected to engage in the following experiments. The gene discussed is IGF2BP2; the disease is hepatocellular carcinoma.